EUCOPE congratulates Ursula von der Leyen on the confirmation of her second term as President of the European Commission. Her leadership and commitment to public health have been instrumental in steering Europe through challenging times. It is now fundamental to build on these accomplishments, delivering… read more
The European Confederation of Pharmaceuticals Entrepreneurs (EUCOPE) announced the joining of three (3) new Associate members on 1 January 2023. The new members joining EUCOPE network are: APCO Worldwide, RareLab and SKC. During the announcement, EUCOPE’s Secretary General Alexander Natz said, “The new year means… read more
Sounds of Science – Episode 11 2022 Year in Review: Our Policy team’s perspectives on the past year in EU Health and a look ahead to 2023 Throughout 2022, there have been successes, challenges, delays and change within the European pharmaceutical industry and we expect… read more
Sounds of Science Podcast – Episode 10 Launch Conditionality: The impact on small and mid-sized companies Within the European Commission’s ongoing review of the General Pharmaceutical Legislation and Orphan Medicinal Products (OMP) Regulation, there are several potentially controversial policy options that aim to enhance access… read more
Sounds of Science Podcast – Episode 7 Unmet Medical Needs (UMN): Towards a new understanding with a focus on underserved areas The topic of unmet medical needs (UMN) is quite high up on the agenda in European health policy these days. Recent literature has identified… read more
Sounds of Science – Episode 6 Overcoming Barriers: Improving Access for Rare Disease Patients through Cross-Border Healthcare The Cross-Border Healthcare Directive (Directive 2011/24/EU) marked a milestone for European patients. It created a legal framework for the patient’s right to seek healthcare in another Member State… read more
Every month, EUCOPE spotlights a member company and the great work they’re doing to advance the life sciences industry and drive innovation to serve patients better. In May, we spoke with Ruediger Gatermann, Senior Director Health Policy & External Affairs Europe, CSL Behring. Ruediger Gatermann… read more
The complexities related to delivering some Advanced Therapy Medicinal Products (ATMPs) most likely will require highly specialized clinical expertise and infrastructures, which currently do not exist in all EU counties. Therefore, relocating or crossing borders often represent the only solution for many patients. A well-developed… read more
The recent years have seen a number of high-end innovative therapies becoming accessible to patients in Europe. These products offer groundbreaking new opportunities to patients living with rare diseases or cancer, with the capacity of often one-time disease-modifying and potentially curative treatments. This new generation… read more
Following a successful launch event, the TRANSFORM MEP Interest Group, a multi-stakeholder alliance of Members of European Parliament, patient groups, academia and industry, published two important documents to lay the foundations of an open discussion on key priorities for gene and cell therapies, namely a… read more
Keep up-to-date on all of the most pertinent policy files and regulatory news around the world of European health technologies with our monthly newsletter – the Innovation Eye-View
You are currently viewing a placeholder content from Facebook. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
You are currently viewing a placeholder content from Instagram. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
You are currently viewing a placeholder content from X. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.